2019 年第 7 期 第 14 卷

莫西沙星溶液雾化吸入治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的效果及对机体相关指标的影响

Therapeutic effect of moxifloxacin nebulized inhalation on chronic obstructive pulmonary disease with type Ⅱ respiratory failure and the effect on related clinical indicators

作者：贾晓佳

英文作者：

单位：100013北京市和平里医院内科

英文单位：

关键词：慢性阻塞性肺疾病；莫西沙星；呼吸衰竭；雾化吸入

英文关键词：

• 摘要：

• 【摘要】目的    研究莫西沙星溶液雾化吸入治疗慢性阻塞性肺疾病（COPD）合并Ⅱ型呼吸衰竭的效果及对机体相关指标的影响。方法    选取2015年4月至2016年7月北京市和平里医院收治的COPD合并Ⅱ型呼吸衰竭患者82例。完全随机分为常规组与莫西沙星组，各41例。常规组给予基础及抗感染治疗，莫西沙星组在常规组基础上给予莫西沙星溶液雾化吸入治疗。治疗后，比较2组患者治疗前后血清炎症因子水平、动脉血气指标、肌酸激酶水平、天冬氨酸转氨酶水平、急性生理学与慢性健康状况评分系统Ⅱ（APACHEⅡ）评分；比较2组疗效与不良反应发生情况。结果    治疗后，莫西沙星组总治愈率明显高于常规组［95.1%（39/41）比78.0%（32/41）］，差异有统计学意义(P<0.05)。治疗后，2组肿瘤坏死因子α、C反应蛋白、动脉血二氧化碳分压、肌酸激酶、天冬氨酸转氨酶、APACHEⅡ评分均明显低于治疗前，且莫西沙星组低于常规组；白细胞介素10、动脉血氧分压明显高于治疗前，且莫西沙星组高于常规组，差异均有统计学意义(均P<0.05)。结论    莫西沙星溶液雾化吸入治疗COPD合并Ⅱ型呼吸衰竭临床效果显著，安全性较高，对动脉血气改善明显，可以有效降低机体炎症反应，降低对心肌细胞损伤，提高机体生理状况。

• 【Abstract】Objective    To analyze the therapeutic effect of moxifloxacin nebulized inhalation on chronic obstructive pulmonary disease(COPD) with type Ⅱ respiratory failure and its effect on related clinical indicators. Methods    Eighty-two COPD patients with type Ⅱ respiratory failure admitted to Beijing Hepingli Hospital from April 2015 to July 2016 were randomly divided into control group and moxifloxacin group, with 41 cases in each group. The control group had routine anti-infective therapy; the moxifloxacin group was treated with nebulized inhalation of moxifloxacin solution on the basis of routine therapy. Serum inflammatory factors, arterial blood gas indexes, creatine kinase, aspartate aminotransferase and Acute Physiology and Chronic Health Evaluation Ⅱ(APACHEⅡ) were analyzed before and after treatment. Therapeutic efficacy and adverse reactions were analyzed. Results    The total effective rate in moxifloxacin group was significantly higher than that in control group［95.1%（39/41） vs 78.0%（32/41）］(P<0.05). After treatment, levels of serum tumor necrosis factor-α, C-reactive protein, arterial partial pressure of carbon dioxide, creatine kinase, aspartate aminotransferase and APACHEⅡ score significantly decreased in both groups; the indexes in moxifloxacin group were significantly lower than those in control group(all P<0.05). Serum level of interleukin-10 and arterial partial pressure of oxygen significantly increased in both groups and they were significantly higher in moxifloxacin group than those in control group(all P<0.05). Conclusion    Nebulized inhalation of moxifloxacin solution treating COPD with type Ⅱ respiratory failure can effectively improve arterial blood gas, reduce inflammatory response, reduce myocardial cell damage and improve patients′ physiological condition with good safety.